SUPN Q3 2023 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SUPNSupernus Pharmaceuticals, Inc.

$3B

Q3 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$154M-13.2% YoY

Gross Profit

$134M87.3% margin

Operating Income

$8M5.3% margin

Net Income

-$16M-10.4% margin

EPS (Diluted)

$-0.29

QoQ Revenue Growth

+13.5%

Cash Flow

Operating Cash Flow

$36M

Free Cash Flow

$36M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$373M

Stockholders' Equity

$912M

Cash & Equivalents

$95M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$154M	$177M	-13.2%
Gross Profit	$134M	$151M	-11.4%
Operating Income	$8M	-$2M	+634.3%
Net Income	-$16M	$2M	-1013.4%

Revenue Segments

Product

$149M49%

Qelbree

$37M12%

GOCOVRI

$33M11%

Oxtellar X R

$30M10%

APOKYN

$22M7%

Trokendi Xr

$21M7%

Manufactured Product, Other

$7M2%

Royalty

$5M2%